Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

BACKGROUND: There is limited real-world evidence that describes patients with newly diagnosed multiple myeloma (NDMM) treated with the bortezomib, lenalidomide, and dexamethasone (VRd) triplet regimen. We evaluated patient characteristics and treatment outcomes among nontransplanted NDMM patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Medhekar, Rohan, Ran, Tao, Fu, Alex Z., Patel, Sharmila, Kaila, Shuchita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386920/
https://www.ncbi.nlm.nih.gov/pubmed/35982416
http://dx.doi.org/10.1186/s12885-022-09980-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386920/
https://www.ncbi.nlm.nih.gov/pubmed/35982416
http://dx.doi.org/10.1186/s12885-022-09980-9

Ejemplares similares